Printer Friendly

IMMUNEX ISSUES INFORMATION UPDATE TO AVOID PATIENT CONFUSION

 IMMUNEX ISSUES INFORMATION UPDATE TO AVOID PATIENT CONFUSION
 This information is provided as background for future stories you may have in preparation on an experimental alpha interferon AIDS compound.
 Certain news reports over the past few months have erroneously called an experimental alpha interferon AIDS treatment "Immunex." This experimental drug is not a product of Immunex Corporation (NASDAQ: IMNX) and use of the name Immunex by the promoters violates Immunex Corporation's trademark and trade name rights. Most important, continued improper use of the name creates confusion among patients and physicians.
 To avoid confusion, the Nation of Islam, U.S. distributor of the product, has renamed the drug IMMUVIRON. Please update your file information with this correct terminology to assist patients.
 Immunex Corporation is a Seattle-based biopharmaceutical company focused on the research, development, manufacture and marketing of products to treat cancer and autoimmune diseases.
 CONTACT: Jason Rubin or Mary McConnon of Immunex, 206-587-0430.
 -0- 7/29/92
 (IMNX) CO: Immunex Corporation ST: Washington IN: MTC SU:


PS-OS -- NY050 -- 4573 07/29/92 11:26 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 29, 1992
Words:174
Previous Article:BIRD CORPORATION DECLARES QUARTERLY DIVIDEND
Next Article:IBM AND INROADS TO SPONSOR COMPUTER CAMP
Topics:


Related Articles
IMMUNEX LAUNCHES WORLD WIDE WEB SITE
Immunex Announces Results of Pivotal Trial for ENBREL in Rheumatoid Arthritis, Confirming Effectiveness
Immunex and Medarex Announce Broad HuMAb-Mouse Licensing Agreement.
Immunex and Wyeth Ayerst Announce Label Update for ENBREL(R).
Immunex Corporation and Genentech, Inc. Join Forces to Develop TRAIL/Apo2L in Cancer.
Immunex Launches Multiple Sclerosis Educational Web Site.
NOVANTRONE(R) One Step Closer to FDA Approval to Treat Multiple Forms Of Multiple Sclerosis.
The 'Immunex All Stars' Celebrate 20 Years of Breakthrough Science.
Immunex Schedules Investor Conferences for August.
Immunex Schedules Investor Conference for September.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters